← Eichor
Study identifier: NCT07296835 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Surgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope

Condition: Kidney Stones  ·  Sponsor: University of Kansas Medical Center

PhaseNA
Planned participants75
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Comprehensive comparative investigations between HugeMed HU30M 6.3 Fr f-URS and traditional approach f-URS devices in RIRS are lacking in an American population. The investigators aim to compare the outcomes of using the 6.3 Fr f-URS versus traditional approach (other f-URS present in our institution) to treat patients with stone burden ≤ 2.5 cm. The findings of this study will expand on the potential advantages and drawbacks of HU30M in enhancing surgical outcomes and patient safety in RIRS procedures. We hypothesize that the use of the HU30M will result in increased cost savings while providing similar stone free rates when compared to traditionally used f-URS devices.

This description comes directly from the study's public registry record.

Talk to the study team

Wilson R. Molina, MD  ·  913-588-8721  ·  wmolina@kumc.edu

Jane Research Project Manager  ·  913-588-8721  ·  jledesma2@kumc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University Of Kansas Medical CenterKansas City, Kansas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07296835